Table 3.

Age-standardized incidence rate of CV/heart diseases in secondary prevention among statin users and statin non-users

Group	ASIR of CV/heart disease in 1999	Summary	Trend 1		Trend2
		AAPC	Years	APC	Years	APC
Total	51.7‰	−3.9 [− 7.4; − 0.4]*	1999–2001	− 13.7 [− 34.4; 13.5]	2001–2013	−2.2 [− 3.8; − 0.6]*
Statin users	69.5‰	−3.4 [− 6.7; 0.1]	1999–2001	− 34.5 [− 62.6; 14.7]	2001–2013	−0.4 [− 3.7; 2.9]
50–59a	28.3‰a	2.6 [−4.3; 9.9]	2001–2013	2.6 [− 4.3; 9.9]
60–79	37.3‰	−0.5 [− 2.8; 1.9]	1999–2013	−0.5 [− 2.8; 1.9]
80 + b	55.9‰b	−7.2 [− 29.0; 21.3]	2004–2013	−7.2 [− 29.0; 21.3]
Statin non-users	52.6‰	−3.2 [−4.4; − 2.0]*	1999–2001	− 14.1 [− 33.8; 11.6]	2001–2013	− 2.3 [− 3.8; − 0.8]*
50–59	37.3‰	−1.8 [−6.7; 3.3]	1999–2013	− 1.8 [− 6.7; 3.3]
60–79	51.7‰	−3.2 [− 4.6; − 1.7]*	1999–2013	−3.2 [− 4.6; − 1.7]*
80+	64.2‰	−3.4 [− 5.0; − 1.8]*	1999–2013	−3.4 [− 5.0; − 1.8]*

^*p < 0.05, ^adata for years 1999 to 2000 were excluded because of the small sample size (N < 100), ^bdata for years 1999 to 2003 were excluded because of the small sample size (N < 100), ASIR age-standardized incidence rate, AAPC average annual percentage change, APC annual percentage change